Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) announced its upcoming participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The company's management team will engage in a fireside chat scheduled for Tuesday, May 20 at 12:00 p.m. ET. Investors can access both the live webcast and a 90-day archived recording of the presentation through Avadel's Investor Relations website at investors.avadel.com.

News Market Reaction – AVDL

-5.84%

-5.84% Session move

In the trading session that priced this news, AVDL declined 5.84%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the H.C. Wainwright 3^rd Annual BioConnect Investor Conference on Tuesday, May 20 at 12:00 p.m. ET.

A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following the conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Austin Murtagh
Precision AQ
Austin.Murtagh@precisionAQ.com
(212) 698-8696

Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162

FAQ

When is Avadel Pharmaceuticals (AVDL) presenting at the H.C. Wainwright BioConnect Conference?

Avadel Pharmaceuticals will present at the H.C. Wainwright BioConnect Conference on Tuesday, May 20 at 12:00 p.m. ET.

How can investors access Avadel Pharmaceuticals' (AVDL) presentation at the H.C. Wainwright Conference?

Investors can access the live webcast and archived recording of the presentation through Avadel's Investor Relations website at investors.avadel.com.

How long will Avadel Pharmaceuticals' (AVDL) H.C. Wainwright Conference presentation be available for replay?

The archived recording of the presentation will be available on Avadel's Investor Relations website for 90 days following the conference.

What type of presentation will Avadel Pharmaceuticals (AVDL) give at the H.C. Wainwright Conference?

Avadel Pharmaceuticals' management will participate in a fireside chat format presentation at the conference.